Loading clinical trials...
Loading clinical trials...
Phase I Trial of Lymphodepletion Followed by Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
Conditions
Interventions
Autologous Tumor Infiltrating Lymphocytes
High-Dose Interleukin 2
Locations
1
United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Start Date
October 7, 2020
Primary Completion Date
January 26, 2023
Completion Date
January 26, 2023
Last Updated
July 3, 2025
NCT04693377
NCT06500455
NCT06066138
NCT07112170
NCT06975293
NCT07281924
Lead Sponsor
Gregory Daniels
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions